{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:46:21Z","timestamp":1761864381023,"version":"3.44.0"},"reference-count":20,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2021,12,4]]},"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:p>This case study discusses a patient who presented with severe lower urinary tract symptoms and pain after commencing immunotherapy for eosinophilic asthma. Initial aetiology was presumed to be infective but cultures were negative. Cross-sectional imaging showed extensive perivesical and periprostatic stranding and inflammation. He was initially treated with antibiotics and anti-inflammatories but a lack of clinical improvement led to a rigid cystoscopy which identified an inflamed, oedematous urothelium which was biopsied. Histology demonstrated extensive, full thickness superficial detrusor inflammation, with marked congestion, oedema and a mixed inflammatory infiltrate in keeping with a severe active chronic non-infectious cystitis, possibly secondary to benralizumab therapy. His benralizumab was stopped and his symptoms completely settled. We believe this is the first described case of severe non-infective cystitis which may be secondary to benralizumab. This case adds to the isolated reports of this rare side effect of some of the newer biological agents in use.<\/jats:p>","DOI":"10.1136\/bcr-2021-244733","type":"journal-article","created":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T10:47:21Z","timestamp":1642416441000},"page":"e244733","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Non-infective cystitis secondary to benralizumab immunotherapy"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6473-8643","authenticated-orcid":false,"given":"Toby","family":"Murray","sequence":"first","affiliation":[{"name":"Urology, Frimley Park Hospital NHS Foundation Trust, Frimley, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben","family":"Haagsma","sequence":"additional","affiliation":[{"name":"Histopathology, Royal Surrey County Hospital NHS Foundation Trust, Guildford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Chetwood","sequence":"additional","affiliation":[{"name":"Urology, Frimley Park Hospital NHS Foundation Trust, Frimley, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,1,17]]},"reference":[{"key":"2025082712503570000_15.1.e244733.1","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/BF02764844","article-title":"Intravesical electromotive drug administration for the treatment of non-infectious chronic cystitis","volume":"8","author":"Riedl","year":"1997","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"key":"2025082712503570000_15.1.e244733.2","unstructured":"Engeler D , Baranowski AP , Berghmans B . EAU guidelines on chronic pelvic pain: EAU, 2021. Available: https:\/\/uroweb.org\/guideline\/chronic-pelvic-pain\/ [Accessed 11 Nov 2021]."},{"key":"2025082712503570000_15.1.e244733.3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1177\/1756287217734167","article-title":"Current best practice in the management of cystitis and pelvic pain","volume":"10","author":"Douglas-Moore","year":"2018","journal-title":"Ther Adv Urol"},{"key":"2025082712503570000_15.1.e244733.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2007.09.019"},{"key":"2025082712503570000_15.1.e244733.5","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2002-0311OC"},{"key":"2025082712503570000_15.1.e244733.6","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-12-204"},{"key":"2025082712503570000_15.1.e244733.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2006.03.031"},{"key":"2025082712503570000_15.1.e244733.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31324-1"},{"key":"2025082712503570000_15.1.e244733.9","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-019-1138-3"},{"key":"2025082712503570000_15.1.e244733.10","doi-asserted-by":"crossref","first-page":"e15868","DOI":"10.1097\/MD.0000000000015868","article-title":"Adverse events of benralizumab in moderate to severe eosinophilic asthma: a meta-analysis","volume":"98","author":"Liu","year":"2019","journal-title":"Medicine"},{"key":"2025082712503570000_15.1.e244733.11","unstructured":"NICE . British National Formulary. Benralizumab 2020."},{"key":"2025082712503570000_15.1.e244733.12","first-page":"101379","article-title":"Successful treatment of eosinophilic cystitis with benralizumab","volume":"33","author":"Cooke","year":"2020","journal-title":"Urol Case Rep"},{"key":"2025082712503570000_15.1.e244733.13","first-page":"97","article-title":"Two cases of nonbacterial cystitis associated with nivolumab, the anti-programmed-death-receptor-1 inhibitor","volume":"17","author":"Shimatani","year":"2018","journal-title":"Urol Case Rep"},{"key":"2025082712503570000_15.1.e244733.14","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s13691-017-0298-6","article-title":"A case of cystitis after administration of nivolumab","volume":"6","author":"Ozaki","year":"2017","journal-title":"Int Cancer Conf J"},{"key":"2025082712503570000_15.1.e244733.15","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/iju5.12211","article-title":"Non-bacterial cystitis with increased expression of programmed death-ligand 1 in the urothelium: an unusual immune-related adverse event during treatment with pembrolizumab for lung adenocarcinoma","volume":"3","author":"Ueki","year":"2020","journal-title":"IJU Case Rep"},{"key":"2025082712503570000_15.1.e244733.16","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.00557","article-title":"Immune checkpoint Inhibitor-Related cytokine release syndrome: analysis of who global pharmacovigilance database","volume":"11","author":"Ceschi","year":"2020","journal-title":"Front Pharmacol"},{"key":"2025082712503570000_15.1.e244733.17","doi-asserted-by":"publisher","DOI":"10.1152\/physiolgenomics.00117.2001"},{"key":"2025082712503570000_15.1.e244733.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2014.04.099"},{"key":"2025082712503570000_15.1.e244733.19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61354-2"},{"key":"2025082712503570000_15.1.e244733.20","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.msard.2016.05.010","article-title":"Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: an integrated analysis of clinical studies","volume":"9","author":"Giovannoni","year":"2016","journal-title":"Mult Scler Relat Disord"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2021-244733","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T19:50:43Z","timestamp":1756324243000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2021-244733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1,17]]},"published-print":{"date-parts":[[2022,1]]}},"alternative-id":["10.1136\/bcr-2021-244733"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2021-244733","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2022,1]]}}}